Back

LVA ablation following the PVI strategy showed better outcomes in diabetic patients with wide LVA compared to narrow LVA: A Sub-Analysis of the SUPPRESS-AF Trial

1 September 2025 (08:15 - 08:25)
Organised by: Logo
Congress Presentation Part of: New insights in catheter ablation of atrial fibrillation Rhythm Control, Catheter Ablation ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Tatsuhisa Ozaki

Osaka National Hospital, Osaka (Japan)

4 More presentations in this session

Presentation thumbnail
Plasma histidine as biomarker for recurrent atrial fibrillation after catheter ablation
Doctor H. Xu (Beijing, CN)
Abstract Slides
Presentation thumbnail
Pulmonary vein reconduction is common in patients undergoing re-ablation after first-time pulsed field ablation for atrial fibrillation
Doctor C. Alhede (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Balancing stroke and bleeding risks: the impact of stopping anticoagulation after aAF ablation - a systematic review and meta-analysis
Doctor S. Koolaji (Stevenage, GB)
Abstract Slides
Presentation thumbnail
Left atrial appendage isolation in catheter ablation of atrial fibrillation: an updated systematic review and meta-analysis.
Doctor M. Nassar (Tanta, EG)
Abstract Slides

Access the full session

Session thumbnail
New insights in catheter ablation of atrial fibrillation
Video

The Event

Event poster

ESC Congress 2025

1 September 2025 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Differential effect of low-voltage area ablation on atrial tachycardia recurrence in diabetic versus non-diabetic patients with persistent atrial fibrillation: sub-analysis of the SUPPRESS-AF Trial
thumbnail
Congress Presentation
Identifying suitable candidates for left atrial low-voltage area ablation in persistent atrial fibrillation: a post-hoc analysis of the SUPPRESS-AF trial
thumbnail
Congress Presentation
Complete vs. incomplete low-voltage area ablation in persistent atrial fibrillation: implications for arrhythmia recurrence

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources